The collaboration aims to accelerate the clinical development of new breast cancer therapies. Novartis research teams will use Cota’s analysis and visualization tools — including the Cota Nodal Address platform, a digital classification system that stratifies patients based on relevant personal and clinical factors — to identify optimal treatments for patients and predict outcomes.
“Analyzing this data using CNAs is a critical factor in enabling healthcare companies to develop and target therapies that increase outcomes and lower the total cost of care,” said Andrew Pecora, MD, founder and executive chairman of Cota. “We’re excited about helping Novartis get deep insight into how patients are getting treatment in practice.”
More articles on population health:
Genomics company taps former Microsoft researcher as chief data scientist
Bigger than opioids: 5 things to know about ‘deaths of despair’ afflicting middle-aged whites
American Heart Association launches data sharing platform
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.